- Home
- SOAR vs BGMS Comparison
SOAR vs BGMS Comparison
Compare SOAR & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SOAR | BGMS |
|---|---|---|
| Founded | 2021 | 1996 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SOAR | BGMS |
|---|---|---|
| Price | $0.33 | $0.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 18.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.74 |
| 52 Week High | $4.36 | $6.70 |
Technical Indicators
Market Signals| Indicator | SOAR | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 38.89 | 36.48 |
| Support Level | $0.28 | $0.74 |
| Resistance Level | $0.73 | $1.12 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 37.83 | 20.00 |
Price Performance
Historical ComparisonAbout SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
About BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.